Amgen Pays $71 Mln to Settle Enbrel, Aranesp Marketing CaseAmgen Pays $71 Mln to Settle Enbrel, Aranesp Marketing Case

Amgen Inc has reached a $71 million settlement with 48 states and the District of Columbia to resolve claims that the company promoted its drugs Enbrel and Aranesp for uses not approved by the FDA. Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news